Edwards Lifesciences Corp (EW) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has...
Edwards Lifesciences Corp (EW) currently trades at a P/E ratio of 47.89 (historical range: 9.35–50.42, median: 26.83), placing it at the 96th percentile — expensive relative to its history, P/S ratio of 8.33 (range: 6.88–8.77, 72th percentile — above its historical average), EV/EBITDA of 103.49 (range: 27.09–109.29, 89th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Edwards Lifesciences Corp's P/E ratio has expanded by 218% over the observed period (from an average of 11.8 to 37.6).
Edwards Lifesciences Corp appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 47.89 | 9.35 | 26.83 | 50.42 | 96th | expensive relative to its history |
| P/S Ratio | 8.33 | 6.88 | 7.97 | 8.77 | 72th | above its historical average |
| EV/EBITDA | 103.49 | 27.09 | 49.98 | 109.29 | 89th | expensive relative to its history |
| FCF Yield | 0.03 | 0.00 | 0.01 | 0.03 | 97th | cheap relative to its history |